Leading respiratory care device maker ResMed Inc. (RMD) is a profit producing machine.

Insider Sale: President of Asia Latin America at ResMed Inc (RMD) Sells 48,000 Shares

Telemedicine stocks could do no wrong during the pandemic. With millions on lockdown and still in need of medical care, telemedicine stocks, like Teledoc Health (NYSE: TDOC ) ran from about $80 to a high of $288.80. At the time, with the pandemic showing no signs of cooling, analysts at McKinsey estimated “that up to $250 billion, or 20% of all Medicare, Medicaid, and commercial outpatient, office, and home health spend could be done virtually.” The Trump Administration signed an executive order to extend telehealth services offered to Medicare beneficiaries. And demand for telehealth exploded 38x higher than before the pandemic, added McKinsey. Even venture capital investments in telemedicine tripled at the time. And then it was all over. Once the crisis ended, so did the massive run in telemedicine stocks. TDOC, for one, now trades at about $8 a share. However, while many are now well off their highs, don’t write them off just yet. With patients still using telemedicine for mental health care, prescription refills, obesity treatment updates, etc. there’s still a good deal of opportunity in telemedicine stocks.

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) has released an update. Resmed Inc has reported an increase in thei…

ResMed Inc. ''s (NYSE: RMD ) adjusted earnings per share in the fourth quarter of fiscal 2024 were $2.08, up 30% year over year. The metric beat the Zacks Consensus Estimate by 2.5%. The adjustments include certain non-recurring expenses/benefits like the amortization of acquired intangibles, restructuring and masks with magnet field safety notification expenses, among others. GAAP EPS in the reported quarter was $1.98, up 26.9% from the year-ago quarter. For the full year, the adjusted EPS of $7.72 topped the Zacks Consensus Estimate by 0.3%. The metric increased 19.9% from the fiscal 2023 adjusted figure. Revenues On a reported basis, fiscal fourth-quarter revenues increased 9% year over year (up 10% at the constant exchange rate or CER) to $1.22 billion. The figure topped the Zacks Consensus Estimate by 0.7%. Full-year revenues were $4.69 billion, a 10.9% improvement on a reported basis from fiscal 2023 (up 11% at CER). The metric came almost in line with the Zacks Consensus Estimate.

ResMed Inc. (NYSE: RMD ) reported fourth-quarter 2024 revenue of $1.22 billion, up 9% year-over-year and up 10% on a constant currency basis, in line with the consensus of $1.22 billion . The growth was driven by increased demand for sleep devices and masks portfolio and strong growth across Software as a service business . Gross margin improved 350 bps to 58.5%; non-GAAP gross margin improved 330 bps to 59.1%, mainly due to reduced freight and manufacturing cost improvements, increased average selling prices, and a favorable product mix. Income from operations increased 38%; non-GAAP income from operations up 30%. The company reported adjusted EPS of $2.08, up from … Full story available on Benzinga.com

Chief executive Mick Farrell says he is confident the company has put to bed investor fears that weight-loss drugs will hurt sales of its sleep apnoea products.

ResMed Inc. (NYSE:NYSE:RMD)Q4 2024 Earnings Conference CallAugust 031, 2024, 04:30 PM ETCompany ParticipantsAmy Wakeham - Chief Communications and Investor…

Sleep apnoea device manufacturer ResMed has continued to see revenue and net income grow, despite short-sellers claiming weight loss drugs threaten its market.

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) has released an update. ResMed Inc. has reported a strong fiscal pe…